Home › Funds › Candriam S.C.A. › GILD

Candriam S.C.A. position in GILD

GILEAD SCIENCES INC · Health Care

Candriam S.C.A. reported holding 1,242,210 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$185.8M, representing 0.84% of its reported portfolio and ranking #22 among its reported holdings. Candriam S.C.A. has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.24M sh
Reported value held$185.83M
Portfolio Weight0.84%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Candriam S.C.A.'s GILD position evolved

Candriam S.C.A. first disclosed a stake in GILD in Q3 2023 at 1,507,856 shares (US$113.0M). The position peaked in Q1 2026 at 1,670,288 shares, worth US$232.8M. Across 13 filings, Candriam S.C.A. increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,242,210 shares valued at US$185.8M — an increase of 50,830 shares quarter over quarter.. Notable position changes include a 49% increase in Q4 2023 (shares fell 9% over the following quarter), a 29% trim in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.51M $113.00M New
Q4 2023 2.24M $181.49M Add
Q1 2024 2.29M $167.39M Add
Q2 2024 2.02M $138.58M Reduce
Q3 2024 2.09M $175.07M Add
Q4 2024 1.72M $159.18M Reduce
Q1 2025 1.57M $176.42M Reduce
Q2 2025 1.51M $167.40M Reduce
Q3 2025 1.62M $179.86M Add
Q4 2025 1.83M $224.89M Add
Q1 2026 1.67M $232.79M Reduce
Q2 2026 1.19M $150.37M Reduce
Q3 2026 1.24M $185.83M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 34 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has Candriam S.C.A. held GILD?

Candriam S.C.A. has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Candriam S.C.A.'s current position in GILD?

As of Q3 2026, Candriam S.C.A. holds 1.24M shares of GILD (GILEAD SCIENCES INC), valued at $185.83M, representing 0.84% of its reported portfolio and ranking #22.

Has Candriam S.C.A. been buying or selling GILD?

In the latest 13F filing (Q3 2026), Candriam S.C.A. increased its position in GILD. The position peaked in Q1 2026 at 1.67M shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.